Jon Coleman Biography and Net Worth

Executive Vice President - Chief Commercial Officer of DexCom

Jon Coleman is Executive Vice President and Chief Commercial Officer at Dexcom.Jon joined Dexcom in 2025 and is responsible for Dexcom’s global commercial organization including global sales, marketing and customer experience.With over 30 years of experience leading global commercial teams across multiple healthcare segments and channels, Jon has an established track record of scaling operations, developing innovative products, entering new markets, and delivering strong growth performance.Prior to Dexcom, Jon served as an executive officer of Masimo Corporation, where he held roles of increasing responsibility across his fifteen-year tenure. This included serving as president of Masimo’s commercial teams where he oversaw the consolidation of its worldwide hospital sales, OEM, alternate care sales, and clinical teams along with the customer service and hospital conversion teams. Jon also held significant roles at Pfizer’s Consumer Healthcare business, leading as vice president and general manager of Canada and the Caribbean region after several years of regional leadership in Asia and Latin America.Since 2018, Jon has been a member of the Board of Trustees for Providence St. Joseph Hospital in Orange, California.Jon earned an M.B.A. from Harvard Business School and a Bachelor of Arts degree in International Relations from Brigham Young University.

What is Jon Coleman's net worth?: The estimated net worth of Jon Coleman is at least $7.34 million as of June 4th, 2026. Mr. Coleman owns 95,450 shares of DexCom stock worth more than $7,338,769 as of June 8th. This net worth evaluation does not reflect any other investments that Mr. Coleman may own. Learn More about Jon Coleman's net worth.
How do I contact Jon Coleman?: The corporate mailing address for Mr. Coleman and other DexCom executives is 6340 SEQUENCE DRIVE, SAN DIEGO CA, 92121. DexCom can also be reached via phone at (858) 200-0200 and via email at [email protected]. Learn More on Jon Coleman's contact information.
Has Jon Coleman been buying or selling shares of DexCom?: During the last ninety days, Jon Coleman has sold $722,628.43 in DexCom stock. Most recently, Jon Coleman sold 4,911 shares of the business's stock in a transaction on Thursday, June 4th. The shares were sold at an average price of $74.13, for a transaction totalling $364,052.43. Following the completion of the sale, the executive vice president now directly owns 95,450 shares of the company's stock, valued at $7,075,708.50. Learn More on Jon Coleman's trading history.
Who are DexCom's active insiders?: DexCom's insider roster includes Donald Abbey (EVP), Steven Altman (Director), Nicholas Augustinos (Director), Andrew Balo (Insider), Quentin Blackford (COO), Michael Brown (EVP), Jon Coleman (EVP), Jon Coleman (Executive Vice President - Chief Commercial Officer), Richard Collins (Director), Matthew Dolan (SVP), Richard Doubleday (EVP), Paul Flynn (EVP), Mark Foletta (Director), Bridgette Heller (Director), Barbara Kahn (Director), Jacob Leach (EVP), Kyle Malady (Director), Jeffrey Moy (EVP), Patrick Murphy (EVP), Steven Pacelli (Insider), Chad Patterson (EVP), Barry Regan (EVP), Kevin Sayer (Executive Chairman, CEO & President), Shelly Selvaraj (SVP), Sumi Shrishrimal (SVP), Jay Skyler (Director), Sadie Stern (EVP), and Jereme Sylvain (CAO). Learn More on DexCom's active insiders.
Are insiders buying or selling shares of DexCom?: During the last twelve months, DexCom insiders bought shares 1 times. They purchased a total of 18,200 shares worth more than $1,001,728.00. During the last twelve months, insiders at the medical device company sold shares 20 times. They sold a total of 68,415 shares worth more than $4,954,788.29. The most recent insider tranaction occured on June, 4th when EVP Jon Coleman sold 4,911 shares worth more than $364,052.43. Insiders at DexCom own 0.3% of the company. Learn More about insider trades at DexCom.
Information on this page was last updated on 6/4/2026.

Jon Coleman Insider Trading History at DexCom

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
6/4/2026	Sell	4,911	$74.13	$364,052.43	95,450
6/3/2026	Sell	4,912	$73.00	$358,576.00	100,361

Jon Coleman Buying and Selling Activity at DexCom

DexCom Company Overview

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions. It has also submitted FDA review for Dexcom Stelo for people with type 2 diabetes. The company has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.

Today's Range

Now: $77.38

$73.00

$78.52

50 Day Range

MA: $64.83

$57.56

$74.87

2 Week Range

Now: $77.38

$54.11

$89.98

Volume

5,074,153 shs

Average Volume

5,341,422 shs

Market Capitalization

$29.86 billion

P/E Ratio

33.01

Dividend Yield

N/A

Beta

1.45